JEWJITSU PEPTIDES: Phage-display architectures, lean-mass framing for GLP‑1 RAs, and nirmatrelvir-derived Mpro reporters

The review on phage‑displayed peptide libraries outlines architectural strategies for generating constrained peptide formats - monocyclic, bicyclic, and multicyclic - and explains why such constraints are pursued: to better mimic protein loop structures and to extend metabolic stability and binding capability for difficult targets such as protein–protein interfaces. The authors survey a range of downstream applications, including targeted therapeutics, molecular diagnostics, and material‑specific peptides for nanotechnology. They also summarize current technical hurdles in library design and selection workflows and discuss how integrating next‑generation sequencing and computational modeling could reshape discovery, while noting these are forward‑looking opportunities rather than demonstrated solutions.

The perspective on lean mass reduction during GLP‑1 receptor agonist–induced weight loss examines how substantial declines in measured lean mass may not equate to pathological muscle loss. It emphasizes limitations of body‑composition methods like DXA in reflecting muscle quality, strength, or function, and proposes mechanical unloading - reduced chronic biomechanical demand after weight loss - as an important explanatory framework. The authors place this idea alongside energy deficit and tissue‑composition changes, propose testable predictions to distinguish adaptive remodeling from sarcopenia, and redirect attention to clinically meaningful endpoints such as strength, mobility, and cardiovascular outcomes rather than lean mass alone.

The Mpro report describes creation of a small library of fluorogenic substrates structurally derived from a standard Mpro reporter and from the clinical inhibitor nirmatrelvir, with the goal of improving assays used to characterize very potent inhibitors. Kinetic testing identified one tetrapeptidic AMC derivative (compound 6) with about ten‑fold improved catalytic efficiency relative to the parent substrate, and this reporter was applied to kinetic characterization of three potent inhibitors. Complementary crystallographic comparisons showed similar molecular interactions with Mpro variants. The authors present substrate 6 as a biochemical tool to support Mpro inhibitor research, noting its role is assay optimization rather than a clinical agent.